EP2753363A4 - Compositions comprising mg53 and methods for the treatment and prevention of airway injury - Google Patents

Compositions comprising mg53 and methods for the treatment and prevention of airway injury

Info

Publication number
EP2753363A4
EP2753363A4 EP12829354.5A EP12829354A EP2753363A4 EP 2753363 A4 EP2753363 A4 EP 2753363A4 EP 12829354 A EP12829354 A EP 12829354A EP 2753363 A4 EP2753363 A4 EP 2753363A4
Authority
EP
European Patent Office
Prior art keywords
prevention
compositions
treatment
methods
airway injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12829354.5A
Other languages
German (de)
French (fr)
Other versions
EP2753363A2 (en
Inventor
Jianjie Ma
Noah Weisleder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Medicine and Dentistry of New Jersey
Rutgers State University of New Jersey
Original Assignee
University of Medicine and Dentistry of New Jersey
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Medicine and Dentistry of New Jersey, Rutgers State University of New Jersey filed Critical University of Medicine and Dentistry of New Jersey
Publication of EP2753363A2 publication Critical patent/EP2753363A2/en
Publication of EP2753363A4 publication Critical patent/EP2753363A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP12829354.5A 2011-09-07 2012-09-06 Compositions comprising mg53 and methods for the treatment and prevention of airway injury Withdrawn EP2753363A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161531708P 2011-09-07 2011-09-07
PCT/US2012/053920 WO2013036610A2 (en) 2011-09-07 2012-09-06 Compositions comprising mg53 and methods for the treatment and prevention of airway injury

Publications (2)

Publication Number Publication Date
EP2753363A2 EP2753363A2 (en) 2014-07-16
EP2753363A4 true EP2753363A4 (en) 2015-03-11

Family

ID=47832768

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12829354.5A Withdrawn EP2753363A4 (en) 2011-09-07 2012-09-06 Compositions comprising mg53 and methods for the treatment and prevention of airway injury

Country Status (3)

Country Link
EP (1) EP2753363A4 (en)
CN (1) CN104066452A (en)
WO (1) WO2013036610A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107266551B (en) * 2016-04-06 2021-03-05 牡丹江友搏药业有限责任公司 MG53 mutant and preparation method and application thereof
TWI781948B (en) * 2016-08-01 2022-11-01 大陸商和其瑞醫藥（南京）有限公司 MG53 mutant and preparation method and use thereof
CN110753557B (en) * 2017-03-22 2024-03-22 神济昌华(北京)生物科技有限公司 TRIM72 uses ubiquitinated FUS protein mutants as potential therapeutic targets for ALS
CN107629123B (en) * 2017-09-07 2020-08-25 北京大学 Nano antibody for resisting MG53 protein and application
CN113474011A (en) * 2018-12-07 2021-10-01 俄亥俄州立创新基金会 Compositions and methods for promoting corneal tissue repair
WO2021015894A1 (en) * 2019-07-25 2021-01-28 Trim-Edicine, Inc. Composition for and method of improving tissue performance
CN115835877A (en) 2020-04-14 2023-03-21 俄亥俄州立创新基金会 Prevention and treatment of organ failure caused by viral infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008054561A2 (en) * 2006-07-11 2008-05-08 University Of Medicine And Dentistry Of New Jersey Proteins, nucleic acids encoding the same and associated methods of use
WO2009073808A2 (en) * 2007-12-04 2009-06-11 University Of Medicine And Dentistry Of New Jersey Compositions and methods to modulate cell membrane resealing

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003063690A2 (en) * 2002-01-31 2003-08-07 Baylor College Of Medicine Secreted caveolin as a marker for prostate cancer
US20110202033A1 (en) * 2006-07-11 2011-08-18 Noah Weisleder Compositions and methods for the treatment and prevention of cardiac ischemic injury
US8058227B2 (en) * 2006-10-03 2011-11-15 Medical University Of South Carolina Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
CN101797375B (en) * 2009-12-02 2013-01-23 北京大学 Application of MG53 protein for preventing and/or treating myocardial ischemia/reperfusion injury

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008054561A2 (en) * 2006-07-11 2008-05-08 University Of Medicine And Dentistry Of New Jersey Proteins, nucleic acids encoding the same and associated methods of use
WO2009073808A2 (en) * 2007-12-04 2009-06-11 University Of Medicine And Dentistry Of New Jersey Compositions and methods to modulate cell membrane resealing

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAI CHUANXI ET AL: "MG53 nucleates assembly of cell membrane repair machinery", NATURE CELL BIOLOGY, MACMILLAN MAGAZINES LTD, vol. 11, no. 1, 1 January 2009 (2009-01-01), pages 56 - 64,1, XP002562736, ISSN: 1465-7392, [retrieved on 20081130], DOI: 10.1038/NCB1812 *
JIA YANLIN ET AL: "Treatment of acute lung injury by targeting MG53-mediated cell membrane repair.", NATURE COMMUNICATIONS 2014, vol. 5, 2014, pages 4387, XP002734684, ISSN: 2041-1723 *

Also Published As

Publication number Publication date
EP2753363A2 (en) 2014-07-16
CN104066452A (en) 2014-09-24
WO2013036610A3 (en) 2013-05-02
WO2013036610A2 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
IL266582A (en) Compositions and methods for the treatment of hemoglobinopathies
HK1209788A1 (en) Methods and compositions for the treatment of lysosomal storage diseases
HK1202416A1 (en) Compositions and methods for preventing and treating oral diseases
IL225471A0 (en) Compositions and methods for the prevention and treatment of cancer
EP2847152A4 (en) Compositions and methods for the treatment of metabolic syndrome
EP2603202A4 (en) Compositions and methods for treatment of taupathy
EP2736528A4 (en) Compositions and methods for the treatment of hiv
EP2665433A4 (en) Devices and methods for the treatment of tissue
EP2771030A4 (en) Compositions and methods for treatment of proteinopathies
EP2688594A4 (en) Methods and compositions for the treatment of cancer
GB2548034B (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
EP2696874A4 (en) Compositions and methods for the treatment of nasal conditions
PL2701645T3 (en) Apparatus for the treatment and/or prevention of corneal diseases
EP2558085A4 (en) Compositions and methods for the prevention and treatment of cancer
IL225793A0 (en) Methods and compositions for the treatment of insulin-associated medical conditions
EP2753363A4 (en) Compositions comprising mg53 and methods for the treatment and prevention of airway injury
HK1211221A1 (en) Formulations for the treatment and prevention of obesity
ZA201408055B (en) Compositions and methods for the treatment of local pain
EP2675275A4 (en) Compositions and methods for the treatment of obesity and related disorders
EP2575824A4 (en) Methods for the treatment and prevention of inflammatory diseases
EP2709632A4 (en) Compositions and methods for the treatment of skin diseases
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
ZA201408065B (en) Compositions and methods for the treatment of diabetes
EP3603631C0 (en) Methods and compositions for the treatment of diverticulosis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140403

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/47 20060101ALI20150127BHEP

Ipc: A61P 9/00 20060101ALI20150127BHEP

Ipc: A61K 31/7088 20060101ALI20150127BHEP

Ipc: A61K 31/105 20060101ALI20150127BHEP

Ipc: A61K 48/00 20060101AFI20150127BHEP

Ipc: A61P 11/00 20060101ALI20150127BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20150209

17Q First examination report despatched

Effective date: 20160614

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171027